BCSs' decisional supports and needs is foundational to supporting quality OET decision making about whether to adhere to OET. Objective: The aim of this study was to examine literature pertaining to OET nonadherence and adverse effects using the Ottawa Decision Support Framework categories of decisional supports and decisional needs because these factors potentially influence OET use. Methods: A systematic literature search was performed in PubMed and CINAHL using combined search terms ''aromatase inhibitors and adherence'' and ''tamoxifen and adherence.'' Studies that did not meet criteria were excluded. Relevant data from 25 publications were extracted into tables and reviewed by 2 authors. Results:
has been little investigation of the process through which that occurs. This review serves as a call to action for providers to provide support to BCSs experiencing OET adverse effects and facing decisions related to nonadherence. Implications for Practice: Findings suggest BCSs prescribed OET have unmet decisional needs, and more decisional supports are needed for BCSs experiencing OET adverse effects.
O ral endocrine therapy (OET) is standard therapy for estrogen receptorYpositive (ER+) breast cancer. 1 An estimated 75% of women with breast cancer receive a recommendation for lifesaving OET such as tamoxifen or aromatase inhibitors (AIs). 1 Oral endocrine therapy is prescribed for ER+ breast cancer to prevent recurrence by blocking certain hormones that fuel cancer growth.
The approach to OET treatment in BCSs with ER+ breast cancer depends on whether a woman is in menopause. Tamoxifen is prescribed to premenopausal, perimenopausal, or postmenopausal women and has been shown to decrease breast cancer recurrence by 41% and mortality by 34%. 2, 3 Aromatase inhibitors, prescribed only for postmenopausal women, have been shown to reduce recurrence by 30% to 41% and metastasis by 16% to 18%, with mortality rate reductions similar to tamoxifen. 2Y4 As a class, the AIs have consistently been shown to improve outcomes for postmenopausal women with hormone receptor-positive breast cancer compared with tamoxifen. 4 Each agent is taken on a daily basis for the duration of a minimum of 5 years, sometimes longer.
Despite the benefits of OET for BCSs with a diagnosis of ER+ breast cancer, many BCSs decide not to take their OET as recommended. 5Y9 The decision to take OET is not a singleevent decision, but a complex process that occurs over time as a series of once-daily decisions or twice-daily decisions. Studies show that 30% to 50% of BCSs who initiate therapy are not adherent to daily or twice-daily pill ingestion, and alarmingly 70% prematurely stop the therapy before the end of the once recommended 5-year period. 2, 3 More recently, trials suggest that 10 years of tamoxifen are better than 5 years and that a program of extended adjuvant therapy of tamoxifen for 5 years followed by AI for 5 years is effective for suitable candidates. 4 This new recommendation causes more concern regarding the 70% early termination rates seen with a 5-year course of therapy.
Understanding a BCS's decisional supports (eg, any support given to meet an identified decisional need) and decisional needs (eg, any need a person may have that results in difficulty making a quality decision) is important to help facilitate adherence to OET, particularly when adverse effects are experienced. 10 Tamoxifen adverse effects include hot flashes, weight gain, loss of libido, and, less commonly, thromboembolic disease or endometrial pathologies. 4Y7,11,12 Aromatase inhibitor adverse effects include hot flashes, arthralgia, increased fractures, rash, and gastrointestinal upset. 4,8,11,13Y16 Understanding the decisional needs and support is a first step in creating a patientcentered intervention to increase the percentage of BCSs that correctly use this potentially lifesaving treatment.
n Purpose and Aims
The purpose of this review was to examine literature pertaining to OET nonadherence and adverse effects using the Ottawa Decision Support Framework categories of decisional supports and decisional needs as requisites for quality decision making. Aims were to use the available literature to (1) summarize the general nature of the studies, (2) summarize the link between prevalence of nonadherence and adverse effects, (3) summarize details of BCSs decisional supports, and (4) summarize thematic categories of BCSs' unmet decisional needs.
Conceptual Framework
The Ottawa Decision Support Framework was the conceptual framework for this study. The framework suggests that quality decisions result when decisional needs (eg, knowledge, expectations, values) are understood and appropriate decisional supports (eg, coaching, counseling, providing facts and probabilities) are provided. 10 Decisional support is defined as any support that is given to meet an identified decisional need. 10 The goal of decisional support is to address modifiable determinants of decision making that are suboptimal. These determinants can include inadequate knowledge, unrealistic expectations, unclear values, unclear norms, unwanted pressure, inadequate support, and inadequate personal and external resources to make the decision. 4, 10, 17 Decisional needs are defined as any need a person may have that results in a difficulty to make a decision. 10 Decisional needs are based on the knowledge, degree of certainty, expectations, and values one may have regarding the decision to be made. 11, 17 n Methods and Search Strategy A systematic literature search was performed in PubMed and CINAHL. The PubMed database was selected because biomedical topics and the sciences are the primary foci of articles contained in this database, and these content areas directly related to the topic for this review. In addition, PubMed includes all articles indexed in MEDLINE. 18 CINAHL was selected instead of OVID for its coverage of full-text nursing medical journals published by many different publishers. OVID searches are limited to articles published only by OVID and its publishing partners. 19 Only peer-reviewed articles were included in the review, so PROQUEST or other dissertation search engines were not included. The search strategy for PubMed and CINAHL databases combined the search terms ''aromatase inhibitors and adherence'' and ''tamoxifen and adherence.'' In order to maximize inclusion, study type and publication date were not limited in the search strategy, and articles including all factors associated with OET nonadherence (not only adverse effects as a single factor) were included. In addition, reference lists of identified review articles were hand searched to identify potentially relevant additional articles. First, titles and abstracts were screened. Second, the full texts of all potentially relevant articles were obtained and read to determine suitability for inclusion. Articles were identified for inclusion by the primary author according to predetermined criteria and then verified by a second reviewer.
Inclusion and Exclusion Criteria
To be eligible for this review, articles had to meet the following inclusion criteria: (1) study population of adult women with a diagnosis of breast cancer, (2) intake of tamoxifen or AIs, (3) quantitative or qualitative analyses between medication and adherence (eg, reported adverse effects attributed to nonadherence), and (4) full-length, original research. All types and stages of breast cancer were included. Excluded were articles that were (1) nonEnglish language, (2) focused solely on reporting only adherence rates and not including factors contributing to nonadherence, (3) reviews, or (4) editorials, opinion papers, or abstracts.
Data Extraction
Data were extracted and organized into 4 separate tables and described below. All extracted data were verified by a second reviewer. Table 1 in analysis contained a general overview of the study characteristics including author, publication year, country where the study occurred, study design, length of study, cancer stage of participants, sample size, and the class of medication (tamoxifen or AI). Table 2 focuses on rates of nonadherence to the OET assessed in each study, the prevalence of adverse effects reported, and whether adverse effects were reported as a reason for nonadherence. Data extracted into Table 3 focused on decisional support participants reportedly received when receiving the OET prescription or at follow-up visits during recommended treatment. Using categories from the ODSF, the table delineates the type, source, timing, and content of provided support. Table 4 focuses on decisional needs. Identified needs are grouped according to 4 thematic categories that emerged from the available data within the articles: (1) regimen (not understanding timing, dose, or duration of OET), (2) beliefs about benefits and risks (OET being unhelpful, not necessary, or other negative or neutral beliefs about OET), (3) inadequate information (insufficient or confusing information, inadequate knowledge of adverse effects, or inadequate knowledge of tumor hormone status), and (4) no one to ask questions (inadequate support to gather information). For studies that contained no detailed information, decisional needs were marked as ''not reported.'' n Results
The search in the PubMed electronic database yielded 222 articles. After title and abstract screening, 99 articles were identified as potentially relevant. After removing 18 duplicates, 81 fulltext versions were screened in detail. Finally, 24 studies were included. The search in the CINAHL electronic database yielded 98 articles. After title and abstract screening, 24 duplicate articles that were found in PubMed were excluded, and 6 articles were screened in detail. Finally, 1 additional article from the CINAHL search was included in the review. The manual search and reference check revealed no further relevant publications. The flowchart in the Figure illustrates the selection process.
Characteristics of Studies
The characteristics of identified studies are summarized in Table 1 5, 7, 8, 11, 12, 15, 16, 22, 25, 27, 30, 32 used quantitative methods, and reported on data collected using standardized selfreport measures. Duration of study time points varied from a single 1-time mailing to 12 years, and not all studies reported this information. Stage of breast cancer ranged from 0 to IV, with not all studies reporting this information. Sample sizes ranged from 30 BCSs to 1531 online posts by BCSs. Participant ages ranged from 18 to older than 85 years. Class of OET studied was fairly well distributed across the relevant literature with 9 studies (36.0%) including both types of OET, 9 studies (37.5%) reporting on tamoxifen, and 7 studies (29.1%) reporting on AIs.
Prevalence of Nonadherence and Adverse Effects
Prevalence of nonadherence varied by drug. As shown in Table 2 , nonadherence rates to tamoxifen ranged from approximately 7.3% to 54.0% and to AI ranged from 5.8% to 61.0%. In studies that reported nonadherence rates to overall therapy and not individually by drug adherence rates, rates were reported as 3.0% to 58.0%.
Prevalence of adverse effects also varied by drug. As shown in Table 2 , tamoxifen adverse effect prevalence ranged from 8.0% to 66.7%, and AI adverse effect prevalence ranged from 18.2% to 66.7%. In studies that reported prevalence to overall therapy and not individually by drug, adverse effect prevalence rates ranged from 3.0% to 69.8%. Four studies did not provide adverse effect prevalence rates but did include narrative description on the impact of experiencing adverse effects on adherence to OET.
Adverse effects were a reason for nonadherence in 23 of the 25 identified studies (92.0%). Studies that focused on both tamoxifen and AIs often did not report adverse effects by drug. Four studies (16.0%) did not include information on specific adverse effects experienced. In addition, 1 study (4.2%) measured only severity and not type of adverse effects, 2 studies (8.3%) were specific to a single adverse effect, and 1 study (4.2%) reported the general experience of adverse effects. Hot flashes were described in 13 studies (54.2%), joint pains in 8 studies (33.3%), fatigue/loss of energy in 7 studies (29.2%), mood problems in 6 studies (25.0%), sexual dysfunction in Some BCSs reported more than 1 adverse effect; some reported none. All answers were included; prevalence unable to be determined.
b
Rates of interruption of AI reported on larger cohort sample not included in analyses.
5 studies (20.8%), night sweats in 4 studies (16.7%), and sleep problems in 2 studies (8.3%).
Decisional Supports
Details on decisional support were absent in 13 of the identified studies (52.0%), because decisional support either was not assessed or was not reported as part of the results. As shown in Table 3 , types and sources of decisional support included verbal information from providers, as well as print or media (Internet, magazines, television, books). The time when decisional support was provided or sought by BCSs was commonly reported as following initial prescription, but some articles also alluded to support being provided prior to initial prescription and also at follow-up visits. Message content was not always described within the articles. In 4 other studies (16.7%), Milata et al information was limited to adverse effects only. In addition, in 4 studies (16.7%), participants specifically described the information they received as being insufficient. Only 1 study (4.2%) included information that BCSs were informed of the importance of taking OET at almost every visit and had the opportunity to discuss adverse effects with their provider. 
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Decisional Needs
Decisional needs are summarized in Table 4 . Decisional needs were not consistently assessed or reported, with 10 studies (40.0%) not reporting any information on decisional needs of BCSs experiencing adverse effects from OET. In the remaining 15 studies (62.5%), the most common categories of decisional needs were inadequate information (n = 7 studies) and belief of benefits and risks (n = 6 studies). One study described anxiety and uncertainty in BCSs regarding their symptom experience, especially when physicians could not explain the exact etiology of their symptoms. 28 Another study included data about BCSs not having anyone to ask questions of and not understanding the duration, timing, or dose of their medication or having anyone available to answer questions. 23 n Discussion
In addition to providing a summary of the general nature of the studies that have been conducted on OET nonadherence in BCSs who are experiencing adverse effects, there are 3 main findings resulting from this review. First, the review summarizes evidence on the relationship between the experience of adverse effects and OET nonadherence. Second, this review demonstrates the absence of decisional supports provided or available to BCSs who are experiencing OET adverse effects. Third, this review demonstrates BCSs have unmet decisional needs in their OET adverse effectYrelated decision-making processes. Each of these findings is discussed in detail below.
Relationship of Nonadherence and Adverse Effects
The relationship between OET nonadherence and adverse effects underscores the importance of this clinical problem and provides evidence supporting the widespread notion that OET adverse effects are a major reason for nonadherence. Reported nonadherence rates are thought to be dependent on a range of parameters, including whether the patients are participating in a clinical trial, the period since initiating treatment, and methods used to assess adherence and medication use. 34 It is likely that rates of nonadherence varied within these studies for similar reasons. Regardless of rates, nonadherence was primarily attributed to the experience of adverse effects. Within this literature, women who reported experiencing OET adverse effects were 2 to 4 times more likely to discontinue OET earlier than 5 years, 5Y7,11,12 and women who reported severe adverse effects were 5 times more likely to discontinue therapy earlier than 5 years. 13 Although adverse effects caused women to switch to a different OET, switching does not prevent further adverse effects, and many women subsequently discontinue even the second OET.
14 Methods used to assess adverse effects of OET varied. Adverse effects were not assessed using comprehensive selfreport measures, which interferes with understanding the true experience of the effect of these drugs. In addition, adverse effects were reported from overall OET, limiting our full understanding of adverse effects experienced by drug. Regardless, our review findings suggest that future research should be focused on improved understanding and elimination of nonadherence caused by adverse effects.
Absence of Decisional Supports
A second major finding of this review was the absence and inadequacy of available decisional supports for this population. The majority of current support was verbal direction from the provider occurring at the time of OET prescription. Details about existing support were limited, but when support was available, it was aimed mostly at the potential experience of adverse effects. Current support seemed to be lacking adverse effect management strategies or stressing the importance of remaining on a regimen even when experiencing adverse effects.
Even when BCSs reported receiving support, they reported it was inadequate. Breast cancer survivors reported they were not given understandable OET-related information. The information they did receive was not sufficient, and they did not have the opportunity to ask questions. Limiting support to information only and not considering additional determinants of decision making such as unrealistic expectations, unclear values, unclear norms, or inadequate personal and external resources increase the potential for poor-quality decisions. 17 The absence of decisional support may be partially due to the lack of decisional support tools for this population. Decisional support tools often come in the form of a decision aid, which is an intervention that helps patients make specific and deliberative choices among options. Decision aids often provide information on treatment options and outcomes relevant to a person's health status, and they include methods to clarify patients' values. 35 The Patient Decision Aids Research Group, affiliated with the Ottawa Hospital Research Institute, is an international research team that designs and tests decision aids and decisional support training programs for patients and health practitioners. The group manages a database of decision aids that can be uploaded and shared if they adhere to established guidelines, including that they (1) meet the definition of a decision aid, (2) are not more than 5 years old, (3) provide references to scientific evidence used, and (4) are publicly available. 10 When the authors searched this database of decision aids that would support the OET decision-making process, only 1 tool was found. This decisional support tool is a decision aid for OET that focuses only on postmenopausal BCSs making the initial decision to initiate therapy and does not take into consideration OET adverse effects or decision making as a process unfolding over time, which can last 5 to 10 years. 36 This further shows that there are inadequate resources for patients and providers to address the adverse effects and resulting impact on adherence to OET.
identify what is important for the decision making, as well as what could be done better in the form of effective decisional support. 10 A revealing finding from this review was the influence of beliefs about OET on adherence. Breast cancer survivors held complex beliefs about their OET, and for a number of BCSs, the decision to discontinue OET seemed to be the result of rational but misguided beliefs about their experience of adverse effects. 6 Attempting to address their unmet decisional needs through seeking inaccurate information likely contributed to the formation of inaccurate beliefs about OET. This finding is important for adherence because it has been shown that BCSs with negative or neutral beliefs about the value of OET were more likely to discontinue it. 5 Breast cancer survivors report having unmet needs regarding information they receive, and they report seeking additional information from sources other than their provider. Breast cancer survivors report having unmet needs regarding information they receive, and they report seeking additional information from sources other than their provider. Although BCSs turn to alternative sources for OETrelated information, these sources may not provide adequate benefit because of uneven quality, conflicting claims, redundancy, and difficulties associated with assessing information accuracy and applicability. 37 n Limitations
Review findings should be interpreted in light of some limitations. First, information on needs and support had to be extracted from Methods and Results sections. Thus, our findings may actually underrepresent BCS supports and needs, suggesting that a more detailed and purposeful study of supports and needs is warranted. A logical next step for research would be to conduct a detailed, basic, descriptive study of BCSs decisionmaking processes and the unfolding of their decisional needs and supports over time. Second, the literature search was limited to English-language articles and a single comprehensive search engine. Search limitations could have limited the search results and potentially omitted additional findings published in other languages or identified in less popular journals not indexed within PubMed or CINAHL.
n Conclusions Overall, the prevalence of adverse effects was quite high and was cited as the major reason for discontinuing OET. Our study confirms that nonadherence to OET due to the experience of adverse effects remains an importance issue, primarily because BCSs experiencing OET adverse effects have unmet decisional needs and lack adequate decisional supports.
This review indicates that more decisional support for BCSs experiencing adverse effects related to OET may be needed. Although we know that adverse effects contribute to BCSs' decisions to stop OET, we do not understand the process through which that occurs. In addition, although we know that BCSs state they receive insufficient information about adverse effects from providers and seek out additional information, we do not fully understand that process or how it may relate to decision making. Future research is needed to further define the concepts of decisional needs and decisional supports for BCSs experiencing adverse effects from OET in order to develop patient-centered materials to improve outcomes of OET therapy. Narrative accounts by BCSs who are experiencing OET adverse effects will provide foundational descriptive information needed to generate interventions to improve quality decision making, such as a decision aid. In order to address the gap in the current decision aids, next steps should include qualitative descriptive research to generate a full understanding of the decision-making process in BCSs who experience OET adverse effects.
n Implications for Practice This review generates some insights for providers who treat BCSs with OETs, particularly when they are assessing OET adherence and adverse effects. The decision to take OET is not a single-event decision, but a complex social process that occurs over time as a series of once-daily decisions or twice-daily decisions over the course of up to 10 years. This decision making is further complicated for BCSs who experience adverse effects. Categories of adverse effects, adherence, decisional support, and decisional needs are all associated with OET decision making, and each of these categories is associated with specific clinical implications as discussed in the following paragraph.
At some point during the OET treatment, a large proportion of BCSs most likely experience some type of adverse effect.
5Y9,11Y15,20Y28 Inadequately managed adverse effects potentially increase nonadherence, leading to an increased risk of breast cancer recurrence. 2, 3 Current methods to assess adverse effects are inconsistent and unstandardized across the research literature. 29 Existing literature suggests providers are failing to document the assessment of adverse effects. Furthermore, this review indicates that little is known about how information regarding adverse effects is communicated. Clinician-recorded adverse effects tend to emphasize serious, life-threatening adverse events rather than patient-reported issues affecting quality of life. Information communicated to women by providers may not fully encompass the true adverse effect burden that may result from OET. Poor or inadequate communication fuels lack of understanding, which can further negatively impact clinicians' abilities to support BCSs in the management of their adverse effects and poor-quality decisions made by BCSs regarding their OET. We recommend that provider assessments include patient report of the experience of adverse effects from OET at every clinical visit, as well as an assessment of adherence.
Decisional support for BCSs can be provided in several different ways. Decisional support from providers may include health messages about the importance of continued OET or include a decisional support tool that addresses the problem (adverse effects from OET), alternatives, benefits, and risks related to deciding to take or not to take prescribed therapies. By providing decisional support to BCSs using these methods, unmet decisional needs may be minimized, leading to a quality decision. Results of this review suggest that the lack of decisional support for BCSs leads to unmet decisional needs and provides a basis to guide health provider encounters with BCSs taking OET.
According to the Ottawa Decision Support Framework, the primary driver of whether individuals are able to make quality decisions is whether their decisional needs are understood and supported. 10 Breast cancer survivors who are inadequately informed about OET adverse effects or the importance of adherence are likely to have unmet decisional needs. By identifying unmet decisional needs, health providers can then be guided toward the types of patient-centered OET health information that BCSs need in order to have adequate support. Providers can determine unmet decisional needs and tailor decisional support provided to BCSs during patient encounters resulting in quality decisions that lead to adverse effect management, ultimately resulting in improved adherence to OET.
